PHARMEXCIL Strengthens India-UAE Partnership

Hyderabad:  The Pharmaceutical Export Promotion Council of India (PHARMEXCIL) has announced its renewed commitment to strengthening the strategic partnership between India and the United Arab Emirates (UAE) in the pharmaceutical sector.

Raja Bhanu, Director General of PHARMEXCIL along with the Advisor to Pharmexcil AVPS Chakravarthi recently had the privilege of meeting Aref Ali Alnuaimi, Consul General of the UAE, in Hyderabad. The meeting highlighted the enduring economic and commercial ties between the two nations, with a particular focus on pharmaceutical exports and collaboration in drug development, formulations, vaccines, and Active Pharmaceutical Ingredients (APIs).

As part of its efforts to enhance this collaboration, PHARMEXCIL is hosting the India Pavilion at Arab Health 2025, one of the most prestigious healthcare and pharmaceutical exhibitions in the region. Scheduled to take place from January 27-30, 2025, at the World Trade Center (WTC), Dubai to be inaugurated by Satish Kumar Siven, Consul General of India to UAE at Dubai on 27th January, 2025 This premier event will feature participation from 65 leading Indian pharmaceutical companies.

The India Pavilion will serve as a showcase for India’s excellence in pharmaceutical manufacturing and innovation, offering a platform for Indian companies to present their products and capabilities to global stakeholders, explore new business opportunities, and deepen engagement with the UAE market.

PHARMEXCIL invites stakeholders from across the healthcare industry to visit the India Pavilion and explore the vast potential of Indian pharmaceuticals.

SOURCE : BioSpectrum India

Related Posts

CPHI Milan launches four special AI, cold chain, contamination control & labelling zones at this year’s event

Milan: CPHI Milan 2026, one of the pharmaceutical industry’s largest global events, has launched four specialist zones designed to connect pharmaceutical companies with the technologies, services and expertise shaping the…

Lilly takes 6 companies to court for selling retatrutide knockoffs

Washington: Eli Lilly’s experimental weight-loss drug retatrutide has yet to be approved by the FDA. But the buzz surrounding the effectiveness of the compound—commonly known as triple-G—has already triggered a…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

CPHI Milan launches four special AI, cold chain, contamination control & labelling zones at this year’s event

CPHI Milan launches four special AI, cold chain, contamination control & labelling zones at this year’s event

Lilly takes 6 companies to court for selling retatrutide knockoffs

Lilly takes 6 companies to court for selling retatrutide knockoffs

FDA Busts Abortion Medicine Racket in Nagpur, Solapur; IndiaMART Directors among 8 Booked

FDA Busts Abortion Medicine Racket in Nagpur, Solapur; IndiaMART Directors among 8 Booked

Gleneagles BGS Hospital honours donor families with India’s largest organ donation recognition wall

Gleneagles BGS Hospital honours donor families with India’s largest organ donation recognition wall

NCB Uncovers Pharmaceutical Fentanyl Diversion Racket in Rural Punjab; Over 18,000 NDPS Drug Units Seized

NCB Uncovers Pharmaceutical Fentanyl Diversion Racket in Rural Punjab; Over 18,000 NDPS Drug Units Seized

Sun Pharma will Need HC Nod for Semaglutide Tablet Launch

Sun Pharma will Need HC Nod for Semaglutide Tablet Launch